Clinical Trial Update: Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial update reporting efficacy and safety data for enteric-coated mycophenolate sodium in kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Enteric-coated Mycophenolate Sodium (EC-MPS) (mycophenolate sodium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED